0001562180-23-000727.txt : 20230130 0001562180-23-000727.hdr.sgml : 20230130 20230130170423 ACCESSION NUMBER: 0001562180-23-000727 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20230126 FILED AS OF DATE: 20230130 DATE AS OF CHANGE: 20230130 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cavalie Fanny CENTRAL INDEX KEY: 0001913484 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39634 FILM NUMBER: 23568772 MAIL ADDRESS: STREET 1: C/O FOGHORN THERAPEUTICS INC. STREET 2: 500 TECHNOLOGY SQUARE, SUITE 700 CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Foghorn Therapeutics Inc. CENTRAL INDEX KEY: 0001822462 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 500 TECHNOLOGY SQUARE STREET 2: SUITE 700 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-586-3100 MAIL ADDRESS: STREET 1: 500 TECHNOLOGY SQUARE STREET 2: SUITE 700 CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2023-01-26 false 0001822462 Foghorn Therapeutics Inc. FHTX 0001913484 Cavalie Fanny 500 TECHNOLOGY SQUARE STE #700 CAMBRIDGE MA 02139 false true false false Chief Strategy/Bus Ops Officer Stock Option (right to buy) 8.38 2023-01-26 4 A false 65000.00 0.00 A 2033-01-25 Common Stock 65000.00 65000.00 D The option vests as to 25% of the underlying shares of common stock on January 26, 2024, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. /s /Allan Reine, M.D., Attorney-in-Fact 2023-01-30 EX-24 2 cavalieex24.txt POWER OF ATTORNEY- CAVALIE LIMITED POWER OF ATTORNEY The undersigned hereby constitutes and appoints Allan Reine, Michael LaCascia and Tara Maduri, and each of them individually, with full power of substitution, as the undersigned's true and lawful attorney-in-fact to: (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934, as amended, or any rule or regulation of the SEC; (2) execute for and on behalf of the undersigned, in the undersigned's capacity as officer and/or director of Foghorn Therapeutics Inc. (the "Company"), Forms 3, 4, 5 and any Schedules 13D or 13G in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder; (3) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such Form 3, 4, or 5 or Schedule 13D or 13G, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and (4) take any other action of any type whatsoever in connection with the foregoing that, in the opinion of each such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by each such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as each such attorney-in-fact may approve in each such attorney-in-fact's discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that each such attorney-in-fact, or each such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that each foregoing attorney-in- fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, 5, and any Schedules 13D or 13G with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to each foregoing attorney-in-fact. [Remainder of page intentionally left blank] IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 16th day of February, 2022. /s/ Fanny Cavalie Name: Fanny Cavalie